Ascelia Pharma Future Growth

Future criteria checks 6/6

Ascelia Pharma is forecast to grow earnings and revenue by 96.9% and 42.3% per annum respectively. EPS is expected to grow by 90.8% per annum. Return on equity is forecast to be 20.6% in 3 years.

Key information

96.9%

Earnings growth rate

90.76%

EPS growth rate

Biotechs earnings growth	27.5%
Revenue growth rate	42.3%
Future return on equity	20.60%
Analyst coverage	Low
Last updated	10 Feb 2026

Recent future growth updates

Recent updates

Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus

Mar 19Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?

Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential

Mar 05Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare, cancer related conditions. What are the underlying business or industry changes driving this perspective?

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26

Earnings and Revenue Growth Forecasts

OM:ACE - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	71	38	39	39	1
12/31/2027	62	17	16	16	3
12/31/2026	87	27	38	38	3
12/31/2025	N/A	-76	-72	-72	N/A
9/30/2025	N/A	-89	-69	-69	N/A
6/30/2025	N/A	-95	-71	-71	N/A
3/31/2025	N/A	-85	-65	-65	N/A
12/31/2024	N/A	-80	-63	-63	N/A
9/30/2024	N/A	-62	-60	-60	N/A
6/30/2024	N/A	-62	-74	-74	N/A
3/31/2024	N/A	-89	-104	-104	N/A
12/31/2023	N/A	-109	-127	-127	N/A
9/30/2023	N/A	-152	-140	-140	N/A
6/30/2023	N/A	-157	-141	-141	N/A
3/31/2023	N/A	-139	-131	-131	N/A
12/31/2022	N/A	-131	-125	-125	N/A
9/30/2022	N/A	-113	-129	-129	N/A
6/30/2022	N/A	-115	-127	-127	N/A
3/31/2022	N/A	-126	-125	-125	N/A
12/31/2021	N/A	-126	-117	-117	N/A
9/30/2021	N/A	-127	-112	-112	N/A
6/30/2021	N/A	-113	-100	-100	N/A
3/31/2021	N/A	-111	-90	-90	N/A
12/31/2020	N/A	-99	-86	-86	N/A
9/30/2020	N/A	-90	-75	-75	N/A
6/30/2020	N/A	-88	-76	-76	N/A
3/31/2020	N/A	-71	-70	-70	N/A
12/31/2019	N/A	-66	-54	-54	N/A
9/30/2019	N/A	-46	N/A	-47	N/A
6/30/2019	N/A	-37	N/A	-30	N/A
3/31/2019	N/A	-30	N/A	-19	N/A
12/31/2018	N/A	-23	N/A	-19	N/A
9/30/2018	N/A	-22	N/A	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: ACE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACE is expected to become profitable in the next 3 years.

Revenue vs Market: ACE's revenue (42.3% per year) is forecast to grow faster than the Swedish market (0.9% per year).

High Growth Revenue: ACE's revenue (42.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACE's Return on Equity is forecast to be high in 3 years time (20.6%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/20 19:58
End of Day Share Price	2026/03/20 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascelia Pharma AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier Sponsored
Lars Hevreng	Danske Bank
Maria Karlsson Osipova	DNB Carnegie Commissioned Research

Ascelia Pharma Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target decreased by 8.7% to kr6.32

Price target decreased by 10% to kr6.65

Forecast breakeven date pushed back to 2026

Price target increased by 10% to kr7.42

Price target decreased by 13% to kr6.71

Recent updates

Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus

Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential

Price target decreased by 8.7% to kr6.32

Price target decreased by 10% to kr6.65

New minor risk - Financial position

We're Hopeful That Ascelia Pharma (STO:ACE) Will Use Its Cash Wisely

Ascelia Pharma AB (publ) Announces Departure of Julie Waras Brogren as Deputy CEO

Ascelia Pharma AB (publ), Annual General Meeting, May 04, 2026

Forecast breakeven date pushed back to 2026

Ascelia Pharma AB (Publ) Files New Patent Application for Orvigance

Ascelia Pharma AB (publ) to Report First Half, 2026 Results on Aug 20, 2026

New major risk - Shareholder dilution

Key Executive recently bought kr82k worth of stock

Price target increased by 10% to kr7.42

Is Ascelia Pharma (STO:ACE) Using Too Much Debt?

New minor risk - Financial position

Price target decreased by 13% to kr6.71

Chief Executive Officer exercised options to buy kr309k worth of stock.

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

Is Ascelia Pharma (STO:ACE) Using Too Much Debt?

Forecast breakeven date moved forward to 2025

New minor risk - Profitability

Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting

Forecast to breakeven in 2027

Ascelia Pharma AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Key Executive recently bought kr55k worth of stock

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (Publ) Presents Late-Breaking Abstract on Sparkle Data At the American Society of Nephrology Kidney Week Congress 2024

New major risk - Shareholder dilution

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

New major risk - Market cap size

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

VP of Pharmaceutical Development recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

Price target increased by 22% to kr9.75

New major risk - Revenue and earnings growth

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Key Executive recently bought kr62k worth of stock

Price target decreased by 61% to kr8.00

New major risk - Revenue and earnings growth

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Price target decreased by 7.1% to kr19.50

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

New major risk - Share price stability

Chief Scientific Officer recently bought kr86k worth of stock

New major risk - Revenue and earnings growth

Insufficient new directors

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Independent Director recently bought kr352k worth of stock

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Price target decreased to kr48.00

Key Executive recently bought kr225k worth of stock

Price target decreased to kr59.00

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Chief Commercial Officer recently bought kr310k worth of stock

Key Executive recently bought kr101k worth of stock

Chief Executive Officer recently bought kr459k worth of stock

Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is Not Reduced by Light Meal

Price target increased to kr64.00

Insufficient new directors

Ascelia Pharma Suspends Clinical Activities in Russia

Key Executive recently bought kr116k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Receives FDA Acceptance of IND Application for Oncoral Clinical Trial

Ascelia Pharma AB (publ) Announces Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Chief Commercial Officer recently bought kr208k worth of stock

Chief Medical Officer recently bought kr260k worth of stock